A Phase I Study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
PANOVA-3: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Ttfields, 150khz Concomitant with Gemcitabine and Nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma
Open-label, Multicenter, Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-Claudin18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects with Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
BAY 1895344 Plus Topoisomerase-1 Top1 Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma SCLC, Poorly Differentiated Neuroendocrine Carcinoma PD-NEC and Pancreatic Adenocarcinoma PDA
A Phase III, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with either
Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer
Phase II Randomized Trial Combining TG01 Vaccine / QS-21 Stimulon With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer TESLA
A Phase II, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab IMAB362 in Combination with Nab-Paclitaxel and Gemcitabine Nab-P + GEM as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma
GRECO-2: A Randomized, Phase II Study of Stereotactic Body Radiation Therapy SBRT in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer